Can Longevity Disrupt Hospitals From Within? — Longevity News Roundup — Week 20, 2026

Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 drugs in progressive MS, Executive Health as a gateway to longevity care, AI-assisted skin regeneration, lab-grown red blood cells, and convergence in aging biomarkers.Neuraly’s NLY01 dosed its first Phase 2 patient with progressive MS in the 120-person, 96-week TAGMS trial. Instead of tracking relapse rates, researchers will use MRI-measured brain atrophy as the primary endpoint to determine whether the GLP-1 receptor agonist can slow neurodegeneration after inflammation is controlled.Biograph’s six-hour executive assessment compresses what they describe as three months of diagnostics into a single visit. Advanced imaging, biomarker panels, cardiac testing, biological age metrics, and cancer screening are bundled into one experience followed by a personalized action plan. ROKIT Healthcare presented one to two-year follow-up data showing sensory restoration, minimal scarring, functional recovery, and zero cancer recurrence after AI-assisted autologous skin reconstruction. The platform uses a patient’s own fat-derived cells combined with AI-guided bioprinting to recreate tissue that behaves like original skin. Hospitals are recognizing that prevention-focused longevity care could erode revenue from late-stage cardiometabolic and surgical interventions. At the same time, they already possess the imaging, labs, multidisciplinary teams, and care coordination required to deliver structured midlife risk assessment programs.Scarlet Therapeutics raised $4 million in seed funding after demonstrating that lab-grown red blood cells survive in circulation as long as donor-derived cells. The company is developing applications that include universal transfusion supply, therapeutic carrier cells, and engineered red blood cells designed for enhanced biological function. Steve Horvath argues that apparent biomarker chaos is narrowing toward a smaller set of aging measures that consistently predict mortality, disease risk, and functional decline. This convergence is critical for trials, clinics, and employer programs that need reliable endpoints to justify prevention strategies.----------News & References:GLP-1 drug enters trial for progressive multiple sclerosis → https://longevity.technology/news/glp-1-drug-enters-trial-for-progressive-multiple-sclerosis/Executive Health program condenses three months of testing into six hours → https://longevity.technology/news/executive-health-program-condenses-three-months-of-testing-into-six-hours/AI regenerative medicine targets skin recovery → https://longevity.technology/news/ai-regenerative-medicine-targets-skin-recovery/Hospitals confront longevity’s quiet disruption → https://longevity.technology/news/hospitals-confront-longevitys-quiet-disruption/Scarlet raises $4m as lab-grown blood matches donor cell survival → https://longevity.technology/news/scarlet-raises-4m-as-lab-grown-blood-matches-donor-cell-survival/‘We are not at consensus but we are at convergence’ → https://longevity.technology/news/we-are-not-at-consensus-but-we-are-at-convergence/